Biological therapy in the reduction of cardiovascular risk in patients with psoriasis
Psoriasis is a chronic inflammatory disease that primarily affects the skin, and its complications include a predisposition to atherosclerosis and cardiovascular disease (CVD), with this risk related to the severity of psoriasis. The mechanisms by which psoriasis predisposes to CVD are not clear. Th...
Saved in:
Main Author: | Andrés Tirado-Sánchez |
---|---|
Format: | Article |
Language: | English |
Published: |
Permanyer
2025-01-01
|
Series: | Revista Médica del Hospital General de México |
Subjects: | |
Online Access: | https://www.hospitalgeneral.mx/frame_eng.php?id=242 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review
by: Annika Smith, et al.
Published: (2025-01-01) -
COVID-19 pandemic and vaccination rate in patients with psoriasis treated with biologics: A single center experience
by: Milčić Danijela, et al.
Published: (2024-01-01) -
Mathematical insights on psoriasis regulation: Role of Th1 and Th2 cells
by: Amit Kumar Roy, et al.
Published: (2018-05-01) -
Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers
by: Andrea Rodríguez-Lopez, et al.
Published: (2024-12-01) -
Real-Life Analysis of Therapeutic Management and Its Correlation With the Dermatology Life Quality Index Score in 108 Patients With Pustular Psoriasis: An Italian Monocenter Study
by: Dario Buononato, et al.
Published: (2025-01-01)